JILIN AODONG(SZ:000623)2022-11-14 03:28Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. primarily focuses on traditional Chinese medicine, accounting for approximately 70% of its business, while chemical drugs contribute around 12-18% [2] - The company has a total of 51 products under research and has obtained 246 production approval documents as of June 30, 2022 [2] - The company has signed a deep cooperation agreement with Xin Xuan Group to promote transparent consumption in the health sector [2] Group 2: Product Performance - The core product, Anshen Bnnao Liquid, has been on the market for nearly 40 years, holding a market share of about 60-70% in its segment, with annual sales nearing 600 million yuan [3] - In 2021, four products achieved sales revenue exceeding 100 million yuan, including Anshen Bnnao Liquid and others [3] - The company aims to develop and cultivate products with sales over 10 million yuan to eventually reach over 100 million yuan [3] Group 3: Financial Investments - The company has become the largest shareholder of GF Securities, holding 1,448,016,667 shares, which is 19.0001% of the total share capital [4] - The investment in GF Securities is considered a core asset that positively impacts the company's performance [4] - The company has also invested in various pharmaceutical companies and established a fund to invest in promising biopharmaceutical projects [4] Group 4: Market Strategy - The company is shifting its marketing strategy to integrate online sales platforms and modern sales models, including e-commerce and micro-businesses [3] - It has accumulated 246 production approval documents for traditional Chinese medicine formula granules, which are being promoted in hospitals nationwide [4] - The company is adapting to changes in the market and regulatory environment to enhance its core competitiveness [4]